100 Bayer Boulevard
689 articles with Bayer
Bayer will present new research from the Company’s oncology portfolio, including Stivarga® (regorafenib) and Vitrakvi® (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
Velum Prime and Movento Manage Nematodes for Better Yields and Improved Plant Health in Pacific Northwest
With the potential to cause up to 90 percent annual yield loss, nematodes can be a key threat to a potato crop.
Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive
Daré may be entitled to up to $310 million in commercial milestone payments plus tiered royalties on net sales in the double-digits
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin
Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria
Bayer receives FDA clearance for expanded use of MEDRAD® Stellant FLEX CT Injection System in Contrast Enhanced Mammography (CEM)
Bayer announced today the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indication of its MEDRAD® Stellant FLEX Computed Tomography (CT) Injection System with Certegra® Workstation for use in Contrast Enhanced Mammography (CEM).
With $1.5 Million Donation From Bayer, Gateway Region YMCA Marks Expansion, Renovation and Renaming of Its North St. Louis, Mo. Facility With Groundbreaking Ceremony
A groundbreaking and dedication ceremony held in St. Louis signaled the start of $2.5 million in renovations for the newly renamed Bayer YMCA.
Fluor Corporation and Bayer placed the final steel beam for Bayer’s new cell culture technology center being constructed in Berkeley, California.
Bayer today announced the publication of an analysis of the PROTECT VIII extension study in which a subset of 33 patients with hemophilia A who received five years of prophylactic treatment with Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) maintained a safety and efficacy profile that was consistent with a prior analysis of the same subset, as well as with an analysis of the pivotal Phase III PROTECT VIII main study
Bayer Fund and St. Louis Area Food Bank Partner to Launch Pilot Food Initiative to Support Students and Families Impacted by Hunger
The New School Food Markets Program will be introduced in the Jennings, Mo. and Cahokia, Ill. School Districts
Bayer enters into collaboration with Children's Hospital of Philadelphia to research novel small molecule therapies for the oral treatment of hemophilia
The partnership will combine CHOP's expertise in hemophilia and coagulation and Bayer's research capabilities.
11/25/2019As usual, it was a busy week for clinical trial updates. Here’s a look.
Bayer Announces National Sponsorship of the American Heart Association and the American Diabetes Association's Know Diabetes by Heart initiative
Bayer announced it has joined Know Diabetes by Heart™, a joint initiative of the American Heart Association and the American Diabetes Association, as a national sponsor.
The results of the Phase III VICTORIA trial set up the potential for the companies to seek regulatory approval for vericiguat.
The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.
Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
Dewpoint's drug platform targets biomolecular condensates, dynamic cellular structures newly understood to be central to many disease mechanisms
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.